Monopar Announces First Patient Enrolled in First-in-Human Phase 1 Trial for Its Novel Radiopharmaceutical MNPR-101-Zr

Core Viewpoint - Monopar Therapeutics Inc. has initiated its first-in-human Phase 1 clinical trial for MNPR-101-Zr, a novel radiopharmaceutical imaging agent targeting aggressive cancers [1][4]. Group 1: Clinical Trial Details - The Phase 1 trial aims to assess the safety and dosimetry of MNPR-101-Zr in up to 12 patients with advanced cancers [7]. - The trial is led by Professor Rodney Hicks at the Melbourne Theranostic Innovation Centre, marking the first human study evaluating a radiolabeled monoclonal antibody targeting uPAR [7]. - The first patient has been enrolled in the trial, indicating progress in the study [8]. Group 2: Target and Significance - uPAR is identified as a significant target in aggressive cancers such as pancreatic, triple-negative breast, and colorectal cancers [2]. - Encouraging preclinical results have highlighted the potential of uPAR as a promising target for treating lethal cancers [8]. Group 3: Company Overview - Monopar Therapeutics is focused on developing innovative treatments for cancer, including MNPR-101-Zr for imaging and MNPR-101 for radio-immuno-therapeutic applications [4].